UnitedHealth Group’s DPCA underscores Not Me program during National Diabetes Month
MINNETONKA, Minn. — The UnitedHealth Group’s Diabetes Prevention and Control Alliance is emphasizing its Not Me program — an employer- and community-based initiative aimed at combating the epidemic of Type 2 diabetes, prediabetes and obesity — in line with National Diabetes Month.
The program encourages Americans to get tested for blood-glucose, cholesterol and blood-pressure levels. These indicators, along with such factors as age, family history and lifestyle habits, may pose as warning signs for those at risk of prediabetes, Type 2 diabetes or obesity, DPCA said.
“There is power in information, and knowing your numbers is the first, all-important step in learning whether you might be at risk for prediabetes or diabetes and saying ‘Not Me’ to these conditions,” DPCA EVP and chief clinical officer Deneen Vojta said. “UnitedHealth Group is helping people prevent and control diabetes so they can focus on leading healthier and more productive lives.”
No comments found
Salix to acquire Oceana Therapeutics
RALEIGH, N.C. — Salix Pharmaceuticals has entered a definitive agreement to acquire all outstanding stock of a provider of gastroenterology and urology therapeutics.
Salix said its acquisition of Oceana Therapeutics’ outstanding stock is valued at $300 million in cash. The transaction is subject to customary conditions to closing (including U.S. antitrust approval) and is expected to be completed in December.
"The acquisition of Oceana expands our product portfolio of innovative products, furthers the diversification of Salix’s base business and provides immediate added revenue," Salix president and CEO Carolyn Logan said. "Oceana markets two differentiated products — Solesta, a first-in-class, biocompatible tissue bulking agent for the treatment of fecal incontinence — and Deflux, the only [Food and Drug Administration]-approved alternative to major ureteral reimplantation surgery for the treatment of vesicoureteral reflux."
No comments found
Mylan acquires rights to Pfizer’s inhaler technology
PITTSBURGH — Generic drug maker Mylan has bought rights to a drug delivery platform made by Pfizer that will allow it to make generic versions of two GlaxoSmithKline respiratory drugs, Mylan said Wednesday.
Mylan announced that it bought exclusive worldwide rights to develop, manufacture and commercialize Pfizer’s generic versions of GSK’s Advair Diskus and Seretide Diskus (fluticasone propionate and salmeterol) using Pfizer’s proprietary dry-powder inhaler delivery system. Both drugs are used to treat asthma and chronic obstructive pulmonary disorder. The deal also will allow Mylan to use the system to develop other branded and generic drugs.
Under the agreement, Mylan will pay for remaining development and capital expenditures to bring the products to market and pay Pfizer $17.5 million plus additional milestone payments. IMS Health estimates that the global market for asthma and COPD prescription drugs is $34 million and growing at about 7% per year. More than half of the market is expected to lose patent protection by the end of 2016, including several blockbuster drugs, including inhaled drugs.
"We are extremely pleased to enter into this agreement with Pfizer, as we believe that inhaler-based products represent a significant opportunity for our generics business and expand our focus on difficult-to-produce, limited-competition products," Mylan president Heather Bresch said.
I have to assume you meant $34B not $34M for ww sales of asthma and COPD products.